Stock Financial Ratios


MGEN / Miragen Therapeutics financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.61
Volume54,600.00
Market Cap ($M)6.37
Enterprise Value ($M)-39.73
Book Value ($M)-0.33
Book Value / Share-0.45
Price / Book-20.25
NCAV ($M)2.85
NCAV / Share3.94
Price / NCAV1.97
Income Statement (mra) ($M)
Revenue3.34
EBITDA-12.51
Net Income-12.67
Balance Sheet (mrq) ($M)
Cash & Equivalents42.80
Cash / Share59.33
Assets89.84
Liabilities8.10
Quick Ratio1.61
Current Ratio1.62
Management Effectiveness (mra)
Return on Invested Capital (ROIC)38.88
Return on Assets (ROA)-1.71
Return on Equity (ROE)38.88
Identifiers and Descriptors
CUSIP60463E103
Central Index Key (CIK)1590750
Industry Groups
SIC 8071 - Medical Laboratories
Other Related CUSIPS
826640203
826640104
Share Statistics
Common Shares Outstanding (M)22.31
Scoring Models
Piotroski F Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Retained Earnings Per Share-120.88
Liabilities Per Share11.22
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Assets Per Share124.53
Treasury Stock Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Property Plant And Equipment Net Per Share0.85
Accounts Receivable Per Share0.88
Equity Per Share54.04
Intangibles Per Share0.00
Cash Per Share59.33
Goodwill Per Share0.00
Additional Paid In Capital Per Share174.62
Cash And Equivalents Per Share59.33
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities And Stock Equity Per Share65.26
Property Plant And Equipment Gross Per Share4.69
Liabilities Other Non Current Per Share0.24
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00
Property Plant And Equipment Per Share0.85
Liabilities Current Per Share9.06
Accumulated Depreciation And Depletion Per Share3.85
Assets Current Per Share123.68
Assets Other Non Current Per Share0.07
Debt Per Share4.39

Related News Stories

miRagen Therapeutics' (MGEN) CEO William Marshall on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time. As a reminder, today’s call is being recorded. (43-0)

Featured Company News - Miragen Therapeutics Announces New Interim Results from Phase-1 Clinical Trial Assessing Safety and Pharmacokinetics of MRG-106

2017-10-16 accesswire
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Miragen Therapeutics, Inc. (NASDAQ: MGEN) ("Miragen"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MGEN. The Company announced on October 13, 2017, new interim results from its ongoing Phase-1 clinical trial, designed to evaluate the safety, efficacy, and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). (58-0)

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

2017-10-13 reuters
* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting (43-0)

miRagen Therapeutics' (MGEN) CEO William Marshall on Q2 2017 Results - Earnings Call Transcript

2017-08-12 seekingalpha
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will be given at that time. As a reminder, this conference is being recorded.

CUSIP: 60463E103